AOD 9604 peptide injections are researched for fat loss. Learn how they work, typical dosing, safety, and how they compare to tesamorelin in the US.
AOD 9604 peptide injections are subcutaneous injections of a synthetic fragment of human growth hormone (hGH), specifically amino acids 176–191. Research suggests this peptide may stimulate lipolysis, the breakdown of stored fat, without raising IGF-1 or affecting blood sugar like full hGH. AOD-9604 is not FDA-approved for human use, so anyone considering it should speak with a healthcare professional first.
What Is AOD-9604 Peptide?
AOD-9604 is a modified piece of the growth hormone molecule. Scientists designed it to isolate the fat-metabolizing effects of hGH while avoiding its growth-promoting and glucose-raising actions. Unlike full hGH, AOD-9604 does not appear to bind the hGH receptor in a way that raises IGF-1 levels.
In research literature, it is also called hGH fragment 176-191. Because of this targeted mechanism, peptide aod 9604 benefits are mainly studied in the context of fat loss and metabolic health, not muscle growth or blood sugar control.
How AOD-9604 Peptide Injections Work
Once injected, AOD-9604 travels through the bloodstream and interacts with fat cells. It appears to mimic the way natural hGH breaks down stored fat into free fatty acids for energy. This process is called lipolysis.
In early animal and human studies, AOD-9604 did not significantly change blood glucose, insulin, or IGF-1 levels. That profile makes it different from full growth hormone, which can cause insulin resistance and acromegaly-like effects when misused.
Many people searching for aod 9604 peptide for weight loss are interested in whether it can reduce fat without diet or exercise. Research does not support that idea. AOD-9604 may support fat metabolism, but it is not a substitute for nutrition, physical activity, or medical weight-loss treatments.
AOD-9604 Peptide Dosage and Injection Protocol
There is no FDA-approved dose of AOD-9604 because it is not an approved drug. Dosing information comes from research studies and community reports, which vary widely. A typical research protocol uses 250 mcg to 500 mcg injected subcutaneously once daily.
Some users follow an aod-9604 peptide dosing chart that recommends injecting in the morning on an empty stomach, while others prefer before bed. The timing is often based on when natural growth hormone peaks. No official guidelines exist for injection timing.
| Research dose | Frequency | Injection site | Notes |
|---|---|---|---|
| 250 mcg | Once daily | Subcutaneous abdomen | Lower end of reported range |
| 300 mcg | Once daily | Subcutaneous abdomen or thigh | Common in early human studies |
| 500 mcg | Once daily | Subcutaneous | Upper end of common user reports |
| 1 mg | Once daily | Subcutaneous | Used in some clinical trials; not standard |
The dose used in published human research has ranged from about 300 mcg to 1 mg per day, but these studies were small and not designed to set a standard. Higher doses do not necessarily mean better results and may increase the risk of side effects.
AOD 9604 Peptide vs Tesamorelin
AOD-9604 and tesamorelin are both peptides studied for fat reduction, but they work differently. Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that is FDA-approved for excess abdominal fat in people with HIV-associated lipodystrophy. AOD-9604 is not FDA-approved for any use.
When comparing aod 9604 peptide vs tesamorelin, the key difference is IGF-1. Tesamorelin raises IGF-1 levels because it stimulates the pituitary to release growth hormone. AOD-9604 does not appear to raise IGF-1. That difference matters for side effects and monitoring.
| Feature | AOD-9604 | Tesamorelin |
|---|---|---|
| Mechanism | hGH fragment 176-191; stimulates lipolysis directly | GHRH analog; increases endogenous GH and IGF-1 |
| FDA status | Not approved for human use | FDA-approved for HIV-related lipodystrophy |
| IGF-1 effect | Little to no increase | Increases IGF-1 |
| Common research dose | 300 mcg–1 mg daily (variable) | 1–2 mg daily by injection |
| Side effects | Injection site reactions, headache, nausea (reported) | Injection site reactions, joint pain, glucose changes |
| Monitoring | Not established | Requires IGF-1 and glucose monitoring |
Safety, Side Effects, and Legal Status
AOD-9604 is not FDA-approved for human use in the United States. It is sold as a research chemical, which means it is not subject to the same purity, sterility, and labeling standards as prescription drugs.
Reported side effects from AOD 9604 peptide injections include redness or pain at the injection site, headache, nausea, and fatigue. More serious risks are unknown because long-term human data are lacking.
People with pre-existing health conditions, pregnant or breastfeeding women, and anyone taking medication should avoid research peptides unless supervised by a doctor. Self-injecting an unapproved peptide carries risks of infection, allergic reaction, and dosing errors.
Where to Buy AOD-9604 Peptide and What to Check
If you search to buy aod-9604 peptide, you will find many online vendors. Not all of them provide third-party certificates of analysis (COA) or follow good manufacturing practices. Purity and sterility can vary widely.
When reading user reviews, look for detailed experiences and independent lab testing rather than marketing claims. No review can replace medical advice or guarantee safety.
Frequently Asked Questions
Is AOD-9604 approved by the FDA for weight loss?
No. AOD-9604 is not FDA-approved for weight loss or any human medical use in the United States. It is legally sold only as a research chemical, not as a prescription or over-the-counter drug.
How much AOD-9604 do people inject?
There is no standard dose. Research studies have used doses ranging from about 300 mcg to 1 mg per day, and community protocols often use 250–500 mcg daily. Because AOD-9604 is unapproved, any dose carries unknown risks and should be discussed with a healthcare professional.
What are the side effects of AOD-9604 peptide injections?
Common reported side effects include injection site reactions, headache, nausea, and fatigue. Serious long-term effects are not well studied. People who inject unapproved peptides also risk infection, allergic reactions, and contamination from poor-quality products.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.